Flag of the European Union EU Clinical Trials Register Help

Clinical trials for melanoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    610 result(s) found for: melanoma. Displaying page 4 of 31.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-004200-38 Sponsor Protocol Number: N11RFA Start Date*: 2012-03-28
    Sponsor Name:NKI-AVL
    Full Title: Phase II study exploring safety and efficacy of the combination of ipilimumab with radiofrequency ablation (RFA) in patients with unresectable uveal melanoma liver metastasis (SECIRA-UM)
    Medical condition: Unresectable uveal melanoma liver metastasis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10030052 Ocular melanomas HLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021885-31 Sponsor Protocol Number: N10TIL Start Date*: 2011-03-24
    Sponsor Name:NKI-AVL
    Full Title: Randomized Phase II Study Using a Non-myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Tumor Infiltrating Lymphocytes and Interleukin-2 in Metastatic Melanoma’
    Medical condition: Patients with metastatic (stage IV) melanoma will be randomized to either treatment arm A (dacarbazine) or treatment arm B (TIL) after metastasectomy and feasibility of culturing of TIL.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-002932-64 Sponsor Protocol Number: APHP200133 Start Date*: 2021-07-23
    Sponsor Name:Assistance Publique - Hôpitaux de Paris (AP-HP)
    Full Title: Prospective randomIzed clinical trial assessing the tolerance and clinical benefit of feCAl tranSplantation in patientS with melanOma treated with CTLA-4 and PD1 inhibitors
    Medical condition: melonoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-007847-28 Sponsor Protocol Number: DERMA-ER-DC08 Start Date*: 2011-09-16
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: A multicenter, randomized, two-armed, open-label Phase III study to evaluate the adjuvant vaccination with tumor RNA-loaded autologous Dendritic Cells versus observation of patients with resected m...
    Medical condition: Patients with resected uveal melanoma showing monosomy 3, free of metastases
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10030052 Ocular melanomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-004011-24 Sponsor Protocol Number: GO27826 Start Date*: 2012-09-14
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VEMURAFENIB (RO5185426) ADJUVANT THERAPY IN PATIENTS WITH SURGICALLY RESECTED, CUTANEOUS BRAF-MUTANT MELANOMA AT HIGH RISK FOR REC...
    Medical condition: Melanoma (patients with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma or patients with Stage IIIC cutaneous melanoma)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025669 Malignant melanoma stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) SE (Completed) CZ (Completed) DE (Completed) FR (Completed) BE (Completed) IT (Completed) ES (Completed) NL (Completed) EE (Completed) PT (Completed) IE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-000681-55 Sponsor Protocol Number: 3475-022 Start Date*: 2015-10-06
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase I/II Study to Assess the Safety and Efficacy of MK-3475 in Combination with Trametinib and Dabrafenib in Subjects with Advanced Melanoma
    Medical condition: advanced or metastatic melanoma - all parts of the trial advanced (unresectable and/or metastatic) solid tumours - Parts 4 and 5
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    21.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002615-15 Sponsor Protocol Number: BGBIL006 Start Date*: 2016-12-14
    Sponsor Name:Helse Bergen HF, Haukeland universitetssjukehus
    Full Title: A Phase Ib/II randomised open label study of BGB324 in combination with pembrolizumab or dabrafenib/trametinib compared to pembrolizumab or dabrafenib/trametinib alone, in patients with advanced no...
    Medical condition: Advanced non-resectable (Stage IIIc) or metastatic (Stage IV) melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014591-21 Sponsor Protocol Number: H8K-MC-JZAO Start Date*: 2010-01-18
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized Phase 3 Study of Tasisulam Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle vs. Paclitaxel as Second-Line Treatment in Patients with Metastatic Melanoma
    Medical condition: Second line metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    12.0 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended) FR (Completed) ES (Prematurely Ended) GB (Prematurely Ended) FI (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended) AT (Prematurely Ended) BE (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000759-41 Sponsor Protocol Number: MO39136 Start Date*: 2018-08-30
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE II TWO COHORT STUDY EVALUATING THE SAFETY AND EFFICACY OF COBIMETINIB PLUS ATEZOLIZUMAB IN BRAFV600 WILD-TYPE MELANOMA WITH CENTRAL NERVOUS SYSTEM METASTASES AND COBIMETINIB PLUS ATEZOLIZU...
    Medical condition: Metastatic Melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) HU (Completed) ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002827-15 Sponsor Protocol Number: A3671009 Start Date*: 2006-01-19
    Sponsor Name:Pfizer Ltd. [...]
    1. Pfizer Ltd.
    2.
    Full Title: Phase 3, open label, randomized, comparative study of ticilimumab and either dacarbazine or temozolomide in patients with advanced melanoma
    Medical condition: Advanced melanoma
    Disease: Version SOC Term Classification Code Term Level
    8.0 10025650 VTc
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed) AT (Completed) BE (Completed) SE (Completed) GR (Completed) CZ (Completed) SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004842-92 Sponsor Protocol Number: SECOMBIT Start Date*: 2016-06-30
    Sponsor Name:FONDAZIONE MELANOMA ONLUS
    Full Title: A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy (ipilimumab/nivolumab) and combo target therapy (LGX818/MEK162) in patients wit...
    Medical condition: Metastatic melanoma and BRAF mutation
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Ongoing) DE (Completed) GR (Completed) AT (Prematurely Ended) GB (GB - no longer in EU/EEA) SE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004120-21 Sponsor Protocol Number: LX01-315 Start Date*: 2008-02-27
    Sponsor Name:Vical Incorporated
    Full Title: A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7® Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metas...
    Medical condition: Recurrent metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Ongoing) NL (Prematurely Ended) BE (Completed) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-004555-21 Sponsor Protocol Number: ARRAY-818-201 Start Date*: 2019-07-08
    Sponsor Name:Array BioPharma Inc.
    Full Title: A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis
    Medical condition: BRAFV600-Mutant Melanoma Brain Metastasis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) NL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000743-41 Sponsor Protocol Number: W00090GE302/EORTC-1902-MG Start Date*: 2021-07-21
    Sponsor Name:PIERRE FABRE MéDICAMENT
    Full Title: Adjuvant encorafenib & binimetinib vs. placebo in resected stage II BRAF V600E/K mutated melanoma: a randomized triple-blind Phase III Study in collaboration with the EORTC Melanoma Group.
    Medical condition: Resected BRAF V600E/K stage II melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019526-14 Sponsor Protocol Number: E7080-G000-206 Start Date*: 2010-11-01
    Sponsor Name:Eisai Ltd
    Full Title: An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
    Medical condition: American Joint Committee on Cancer unresectable stage III or stage IV melanima and disease progression with subjects not harboring the V600E-BRAF mutation with disease progression following first l...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002499-14 Sponsor Protocol Number: CA017-055 Start Date*: 2018-03-01
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized, Double-blind Study of BMS-986205 Combined with Nivolumab versus Nivolumab in Participants with Metastatic or Unresectable Melanoma that is Previously Untreated
    Medical condition: Metastatic or Unresectable Melanoma that is Previously Untreated
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) ES (Completed) GB (Completed) IE (Completed) CZ (Completed) GR (Completed) PL (Completed) FR (Completed) Outside EU/EEA IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000305-76 Sponsor Protocol Number: CMEK162X2111 Start Date*: 2012-09-03
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: A phase Ib/II open-label, multi-center study of the combination of MEK162 plus AMG 479 (ganitumab) in adult patients with selected advanced solid tumors
    Medical condition: colorectal adenocarcinoma. metastatic pancreatic adenocarcinoma melanoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033599 Pancreatic adenocarcinoma metastatic LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053571 Melanoma LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052360 Colorectal adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Prematurely Ended) BE (Completed) FR (Completed) DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002520-16 Sponsor Protocol Number: MK-7902-003 Start Date*: 2018-11-28
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in...
    Medical condition: Unresectable Stage III and Stage IV melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) FR (Completed) GB (GB - no longer in EU/EEA) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002245-12 Sponsor Protocol Number: EORTC 18021 Start Date*: 2005-01-27
    Sponsor Name:European Organisation for the Research and Treatment of Cancer
    Full Title: Intravenous versus intra-arterial fotemustine chemotherapy in patients with liver metastases from uveal melanoma: a randomized phase III study of the EORTC Melanoma Group.
    Medical condition: Uveal melanomas with specific hepatic tropism
    Disease: Version SOC Term Classification Code Term Level
    13.1 10015919 - Eye disorders 10030052 Ocular melanomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006051-12 Sponsor Protocol Number: ICORG 06-03 Start Date*: 2007-04-04
    Sponsor Name:ICORG
    Full Title: PHASE II TRIAL OF THE MULTI-DRUG RESISTANCE PROTEIN MODULATING AGENT SULINDAC IN COMBINATION WITH EPIRUBICIN IN PATIENTS WITH ADVANCED MELANOMA
    Medical condition: Metastatic malignant melanoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027480 Metastatic malignant melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 19:25:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA